Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

NCT03913559 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Closed due to slow accrual

Conditions

Acute Lymphoblastic Leukemia

Interventions

DRUG: Inotuzumab ozogamicin
DRUG: Methotrexate
DRUG: Hydrocortisone
DRUG: Cytarabine
DRUG: Diphenhydramine
DRUG: Acetaminophen
DRUG: Methylprednisolone

Sponsor

St. Jude Children's Research Hospital

Collaborators

[object Object]